Resource impact statement
No significant resource impact is anticipated
We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population).
This is because the population eligible for brigatinib is small (up to 150 people). The guidance states “clinical experts explained that fewer people are starting treatment on crizotinib because of the availability of ceritinib and alectinib. Therefore, the population eligible for brigatinib after crizotinib is small and will decrease as fewer people start treatment with crizotinib.”
The company has a commercial arrangement (simple discount patient access scheme). This makes brigatinib available to the NHS with a discount. The size of the discount is commercial in confidence. For enquiries about the patient access scheme please contact: DSO-UK@takeda.com.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: